Aegerion Pharmaceuticals Announces Key Additions to Medical Affairs and Drug Safety
June 16, 2015 16:10 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 16, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
June 11, 2015 08:50 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 11, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Announces Presentation at the Jefferies 2015 Healthcare Conference
May 27, 2015 17:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 27, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Achieves Primary Endpoint in Phase III Study of Lomitapide in Japanese Patients With Homozygous Familial Hypercholesterolemia (HoFH)
May 26, 2015 07:09 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 26, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel therapies for...
Aegerion Pharmaceuticals Announces Resignation of Chief Financial Officer
May 14, 2015 17:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
May 11, 2015 16:10 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 11, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Announces First Quarter 2015 Financial Results
May 04, 2015 16:10 ET
|
Aegerion Pharmaceuticals, Inc.
- Company records $59.4 million in total net product sales -
- JUXTAPID® net product sales of $57.3 million in the first quarter of 2015 represents 112% growth over the first quarter of 2014...
Aegerion Pharmaceuticals to Present at Upcoming Investor Conferences
May 04, 2015 07:55 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 4, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals to Announce First Quarter 2015 Financial Results on Monday, May 4
April 21, 2015 16:15 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 21, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
April 14, 2015 17:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 14, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...